Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration
XTalks
AUGUST 30, 2022
Global sales of over-the-counter and prescription products related to central nervous system (CNS) disease added up to $86 billion in 2019. Consider targeting your therapies that fail to be orally bioavailable and brain penetrant. The return of cell therapy-iPSCs (induced pluripotent stem cells) and genetically altered delivery cells.
83 
Let's personalize your content